Literature DB >> 15999491

[Clinical analysis of 87 cases of testicular tumor].

Lian-Wen Zheng1, Fu-Biao Li, Rui-Zhi Liu, Ri-Gala Ji, Zhong-Wen Zhao.   

Abstract

OBJECTIVE: To improve the diagnosis and treatment of testicular tumor.
METHODS: Eighty-seven cases of testicular tumor were retrospectively studied.
RESULTS: Of the total number, 79 cases were pathologically diagnosed as germ cell tumor (90.1%), among which there were 44 cases of seminoma (55.7%) and 7 cases of benign tumor (8.1%). Nonseminoma germ cell tumor (NSGCT) was found mainly among those under 5 and from 18 to 40 years of age, while seminoma chiefly among those beyond 17, and testis tumor was rare among those between 5 and 17 years old (1 case only). Three-year and 5-year survival rates of seminoma and NSGCT were 90.6% and 81.3%, and 83.3% and 56.7%, respectively.
CONCLUSION: (1) Testicular tumors are mostly germ cell tumors. (2) NSGCT develops mainly among those under the age of 5 and from 18 to 40. (3) Seminoma is rare in those under 18. (4) Testicular tumor rarely develops among those between 5 and 17 years old. (5)Three-year and 5-year survival rates for seminoma are higher than those for NSGCT.

Entities:  

Mesh:

Year:  2005        PMID: 15999491

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  3 in total

1.  A 20-year retrospective study of histopathologic patterns of gonadal germ cell tumors in males in the University of Benin Teaching Hospital.

Authors:  Odokuma Emmanuel Igho
Journal:  Niger Med J       Date:  2015 Nov-Dec

2.  Analysis of the prognosis of patients with testicular seminoma.

Authors:  Wei Dong; Wang Gang; Miaomiao Liu; Hongzhen Zhang
Journal:  Oncol Lett       Date:  2015-12-30       Impact factor: 2.967

3.  The value of testicular ultrasound in the prediction of the type and size of testicular tumors.

Authors:  Abraham Shtricker; David Silver; Elias Sorin; Letizia Schreiber; Nachum Katlowitz; Alexander Tsivian; Kalman Katlowitz; Shalva Benjamin; Abraham Ami Sidi
Journal:  Int Braz J Urol       Date:  2015 Jul-Aug       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.